Neogenomics Laboratories

NeoGenomics News

Enhancing the NeoGenomics Client Services Experience

NeoGenomics has implemented enhancements to the Client Services experience designed to connect clients with the most appropriate support resource more quickly and efficiently.
As part of our ongoing commitment to service excellence, callers may notice additional routing options when contacting Client Services. These enhancements are intended to better align inquiries with the team members best equipped to assist based on the type of support needed.

Benefits of these enhancements include:
Faster connection to the most appropriate support resource
Fewer transfers between teams
Improved response efficiency
Better access to specialized support
Continued investment in the overall client experience

Whether you are calling about order status, reports, specimen pickups, supplies, account updates, technical support, or other inquiries, the enhanced routing experience is designed to make it easier to get the right assistance at the right time.
Our Client Services team, Patient Support team, phone numbers, and support channels remain unchanged.
At NeoGenomics, we remain committed to continuously improving the way we serve our clients and their patients. These enhancements represent another step forward in delivering a simpler, more effective support experience.

NeoGenomics Client Services
FISH Signal Guide v22 - 8/31/26

FISH Signal Guide v22


A new version of the FISH Signal Guide is now available.  Abnormal patterns and Cutoff % have been updated for multiple assays.  Please download the updated guide under Documentation for your reference.


NeoNEWS 9/9/2026

September 9, 2026

Medicare Coverage Expanded for RaDaR® ST in Immunotherapy Monitoring

NeoGenomics has received expanded coverage through the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) for RaDaR ST monitoring of response to immune checkpoint inhibitor therapy in patients with late-stage solid tumors.

Immunotherapy continues to transform treatment across numerous cancer types. However, assessing response can present unique challenges. Patients may experience pseudoprogression, delayed response, or mixed response patterns that make conventional imaging difficult to interpret and can complicate treatment decisions.

RaDaR ST provides clinicians with personalized, longitudinal ctDNA monitoring that may offer earlier molecular insight into treatment response dynamics while complementing imaging and clinical evaluation.

This expanded Medicare coverage represents a meaningful step toward improving access to molecular monitoring for patients receiving immunotherapy and supports more informed treatment decisions throughout the care journey.

c-MET CDx for NSCLC

Our expanded NSCLC testing menu now features the c-MET CDx IHC assay, available as an add-on to PanTracer™ Tissue orders for detailed biomarker profiling in lung cancer patients.


Learn more about the value of HGF Receptor (c-Met) testing for lung cancer management at https://www.neogenomics.com/providers/test/APH-CMET-01AX/c-met-cdx-for-nsclc/
For a complete list of recent test updates, click here for a downloadable document to view the impacted interface test codes.



You have exceeded the maximum number of log in attempts and your account has been locked. Please click on Forgot Password to proceed or contact Client Services at 1-866-776-5907, option 3 for assistance. Thank You.